Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in oncology & hematology will be read downstream.
Oncology & Hematology
ICG works across oncology and hematology environments where clinical differentiation, biomarker logic, regulatory sequencing, treatment-setting capacity, access, and commercial organization form one decision system.
The work includes oncology competitive intelligence, trial and filing assessment, biomarker and companion-diagnostic strategy, market access, launch preparation, field-force architecture, and longitudinal portfolio monitoring.
One Disease System. Multiple Adoption Thresholds.
An oncology asset is not read as a molecule in isolation. Its trajectory may depend on trial design, comparator choice, testing, treatment setting, manufacturing configuration, reimbursement, site capacity, and the organization required to move evidence into practice.
ICG reconstructs those dependencies before they are divided into clinical, regulatory, access, medical, and commercial workstreams. The purpose is to identify the thresholds that determine adoption, sequencing, and portfolio value.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across oncology & hematology.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Immuno-Oncology Trial and Filing Strategy in Small-Cell Lung Cancer
- Competitive Development Assessment of Subcutaneous PD-(L)1 Therapies
- Clinical-Readout and Label-Scenario Assessment in Endometrial Cancer
- Trial-Design Assessment for T-Cell Engagers in CLL and DLBCL
- Biomarker and Testing Architecture for EGFR-Mutated Non-Small-Cell Lung Cancer
- Clinical-Development Landscape for Novel Modalities in Oncology
Regulatory, Access & Adoption
- Payer Strategy for Intravesical and Immuno-Oncology Therapies in Urothelial Carcinoma
- Market Development and Site-Expansion Strategy for Radioligand Therapy in Prostate Cancer in the United States
- Community Adoption of T-Cell Engagers in CLL and DLBCL
- Market-Access Architecture for Multiple-Myeloma Therapies in Emerging Markets
- Companion-Diagnostic Architecture for PARP Inhibitors Across Solid Tumors
- Reimbursement and Treatment-Pathway Assessment for Oncology Therapies in Selected International Markets
Launch & Commercial Architecture
- Global Organization and Value-Based Pricing Architecture for Immuno-Oncology
- Commercialization Architecture for Subcutaneous Oncology Therapies in the United States, Europe and China
- Field-Force Architecture for a KRAS Inhibitor in the United States
- Oncology Field-Force Architecture in Spain
- Launch and Field-Force Strategy for a Multiple-Myeloma Therapy
- Launch Strategy for Solid-Tumor Assets in Turkey and Saudi Arabia
Manufacturing, Delivery & Systems
- Manufacturing and Administration Architecture for Subcutaneous Oncology Formulations
- Treatment-Site Capacity and Referral Architecture for Radioligand Therapy
- Digital-Pathology Adoption and Clinical-Workflow Architecture in Oncology
- Diagnostic-Platform Adoption for PD-L1 and Other Oncology Biomarkers
- Supply and Administration Architecture for Enzyme-Replacement Therapy in Acute Lymphoblastic Leukemia
- Manufacturing Readiness for a Subcutaneous Immuno-Oncology Therapy
Longitudinal Monitoring & Portfolio
- Longitudinal KIQ Monitoring Across Lung, Prostate and Hematologic Cancers
- Competitive Development Assessment in Multiple Myeloma
- Immuno-Oncology Landscape in Colorectal Cancer
- Pipeline Assessment of Novel Assets in Solid Tumors
- Clinical-Readout and Filing Monitoring in Small-Cell Lung Cancer
- Portfolio Monitoring Across PD-(L)1, Anti-TIGIT and Bispecific Therapies
Oncology & Hematology Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.